doi:10.1186/s12866-024-03386-2...
BioMed Central
Mycology
2024
3/7/2024
This study investigated the influence of bacterial cyclic lipopeptides (LP; surfactins, iturins, fengycins) on microbial interactions.
The objective was to investigate whether the presence of bacteria inhibits fungal growth and whether this inhibition is due to the release of bacterial metabolites, particularly LP.
Selected endophytic bacterial strains with known plant-growth promoting potential were cultured in the presence of Fusarium oxysporum f.sp.
strigae (Fos), which was applied as model fungal organism.
The extracellular metabolome of tested bacteria, with a focus on LP, was characterized, and the inhibitory effect of bacterial LP on fungal growth was investigated.
The results showed that Bacillus velezensis GB03 and FZB42, as well as B. subtilis BSn5 exhibited the strongest antagonism against Fos.
Paraburkholderia phytofirmans PsJN, on the other hand, tended to have a slight, though non-significant growth promotion effect.
Crude LP from strains GB03 and FZB42 had the strongest inhibitory effect on Fos, with a significant inhibition of spore germination and damage of the hyphal structure.
Liquid chromatography tandem mass spectrometry revealed the production of several variants of iturin, fengycin, and surfactin LP families from strains GB03, FZB42, and BSn5, with varying intensity.
Using plate cultures, bacillomycin D fractions were detected in higher abundance in strains GB03, FZB42, and BSn5 in the presence of Fos.
Additionally, the presence of Fos in dual plate culture triggered an increase in bacillomycin D production from the Bacillus strains.
The study demonstrated the potent antagonistic effect of certain Bacillus strains (i.e., GB03, FZB42, BSn5) on Fos development.
Our findings emphasize the crucial role of microbial interactions in shaping the co-existence of microbial assemblages.
Assena, Mekuria Wolde,Pfannstiel, Jens,Rasche, Frank, 2024, Inhibitory activity of bacterial lipopeptides against Fusarium oxysporum f.sp. Strigae, BioMed Central